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????????????
The ultimate goal of antihypertensive therapy is not 
only to normalize the blood pressure level but also to 
prevent end-organ damage, such as cardiac hypertro-
phy and renal dysfunction, and to prevent the cardio-
vascular disease, such as stroke and myocardial infarc-
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???????
In the treatment of hypertension, care should be taken for preventing of hypertensive organ injuries as 
well as lowering blood pressure to the adequate level in order to reduce the risk of cardiovascular diseases. 
The purpose of this study is to examine the effects of angiotensin II receptor blockers （ARB）, calcium chan-
nel blockers （CCB） and their combination on the development of cardiovascular organ injuries in spontane-
ously hypertensive rats （SHR）. Four groups of male 8-week-old SHR （n＝9 each） were given vehicle（con-
trol）, 10 mg/kg azelnidipine （AZL）, 10 mg/kg olmesartan （OLM, n＝9）, or the combination of AZL and 
OLM（5 mg/kg each）for 12 weeks, and their effects on cardiovascular organ injuries were evaluated. Tail-
cuff blood at 12 weeks was similarly lowered by AML, OLM and the combination therapy（148, 143 and 
143 mmHg, respectively）as compared with the control SHR （198 mmHg）. Pulse rate was significantly less 
in the AZL group but not in the OLM group or the combination therapy group than in the untreated con-
trol group （−27, −12, ＋6 bpm, respectively）. The cardiac ventricular weight （AZL −12％, OLM −15％, 
combination −18％ vs. control） and aortic thickness （AZL −17％, OLM −16％, combination −19％ vs. con-
trol） were reduced by similar extents in the three groups given antihypertensive treatments. Regarding the 
myocardial fibrosis, left ventricular hydroxyproline content was reduced in the OLM and the combination 
groups but the change was not significant in the AZL group （AZL −14％，OLM −30％, combination −27
％ vs. control）. In the echocardiographic evaluation of cardiac function, the index of left ventricular diastolic 
function is significantly improved in the OLM and the combination groups but not in the AZL group, while 
the index of systolic function was not different between the four groups. It is suggested that the antihyper-
tensive therapy including ARB is superior to the monotherapy by CCB in preventing the myocardial fibro-
sis and preserving the left ventricular diastolic function.
???? ????： hypertension, spontaneously hypertensive rat, angiotensin II receptor antagonist, calcium 
channel blocker, left ventricular hypertrophy, arteriosclerosis
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tion. Therefore, the efficacy of antihypertensive drugs 
on inhibition of hypertensive tissue injuries and preser-
vation of cardiovascular organ function has to be taken 
into consideration in order to achieve maximal im-
provement of long-term prognosis of hypertensive pa-
tients. In the real world clinical practice, angiotensin II 
receptor antagonists （ARB） and long-acting calcium 
channel blockers （CCB） are widely used for the treat-
ment of hypertensive patients because these classes of 
antihypertensive drugs have few chances to cause ad-
verse effects. In addition, CCB exerts consistently cer-
tain hypotensive effects by dilating arteries directly 
and ARB is expected to have protective effects against 
the cardiac and the renal injuries partially by the 
mechanism independent of blood pressure lowing1,2）. 
Thus, it is obviously important to collect the informa-
tion as to the effects of CCB and ARB on the develop-
ment and the progression of hypertensive injuries in 
cardiovascular organs such as the heart, the kidneys 
and the arteries.
It should be also kept in mind that generally only 
one third of hypertensive patients achieve the blood 
pressure level lower than 140/90 mmHg with a single 
antihypertensive agent irrespective of the class of drug 
used and two thirds of patients require a combination 
of two or more drugs in order to obtain adequate blood 
pressure reduction3,4）. Therefore, it is also a matter of 
concern to delineate the therapeutic efficacy of combi-
nation therapy especially with ARB and CCB in terms 
of protecting cardiovascular organs from hypertension. 
In this experimental study, the efficacies of CCB, ARB 
and their combination therapy were examined and 
compared focusing on the inhibition of cardiovascular 
organ injuries in spontaneously hypertensive rat
（SHR）which is assumed to be an appropriate animal 
model of human essential hypertension.
???????
Treatment of rats
Male 8-week-old SHR （n＝36） were purchased from 
Charles River Japan （Atsugi, Kanagawa, Japan）. They 
were fed standard chow and tap water, and were 
housed in a temperature- and light-controlled room 
throughout the study period. They were divided into 
4 groups of 9 SHR each. As a dihydropyridine deriva-
tive CCB, 10 mg/kg azelnidipine （AZL） suspended in 
0.5 ml of 0.5％ methyldellulose was given once daily by 
gastric tube in morning hours to 9 rats. As an ARB, 
10 mg/kg olmesartan （OLM） was given in the similar 
way to another 9 rats. In addition, 5 mg/kg AZL and 
5 mg/kg OLM were simultaneously given in 9 rats of 
the combination therapy group, and 9 rats of the con-
trol group were given vehicle.
The treatments were continued for 12 weeks and 
the systolic blood pressure was measured biweekly 
during the study period using the tail-cuff method. At 
the end of 12-week period, the rats were evaluated for 
the physiological, biochemical and histological evalua-
tions described below. The experiments were per-
formed in accordance with the institutional guide for 
care and use of laboratory animals, and the study pro-
tocol was approved by the institutional animal research 
committee.
Echocardiography
After 12 weeks, transthoracic echocardiographic 
studies were performed under light anesthesia with in-
traperitoneal injection of ketamine HCl（10 mg/kg）and 
xylazine （10 mg/kg）. Two-dimensional echocardiogra-
phy and M-mode tracing were recorded at the level of 
the papillary muscles using a Toshiba（Tokyo, Japan）
SSH-260A unit with a 7.0 MHz transducer placed on 
the shaved left hemithorax of the rats in the left decu-
bitus position. M-mode measurements included left 
ventricular end-systolic and end-diastolic diameters
（LVDs, LVDd）, end-diastolic left ventricular posterior 
wall thickness （PWT）, and interventricular septal 
thickness （IVST）. Midwall fractional shortening 
（mFS） was calculated as follows5,6）：mFS＝［（LVDd＋
IVST/2＋PWT/2）−｛（LVDd＋IVST/2＋PWT/2）3−
LVDd3＋LVDs3｝1/3］/（LVDd＋IVST/2＋PWT/2）. The 
values of mFS were multiplied by 100 and expressed 
as ％ values.
Pulsed-wave Doppler spectra of mitral inflow veloci-
ties were recorded from the apical 4-chamber view 
with the sample volume placed near the tips of the mi-
tral leaflets and adjusted to the position where the ve-
locity was maximal and the flow patterns were lami-
nar. The Doppler spectra were recorded on paper at 
100 mm/s and analyzed off-line to determine peak ear-
ly diastolic filling velocity（E）and peak filling velocity 
at atrial contraction（A）. The heart rate was main-
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tained around 300 bpm with the anesthesia during the 
recording, which enabled the separation of E and A 
wave peaks in each rat. Measurements represent the 
mean of at least 3 consecutive cardiac cycles, and the 
E/A ratio was used for the evaluation of left ventricu-
lar diastolic function7）.
Biochemical Assay
After performing the echocardiogram, blood samples 
were drawn from the inferior vena cava, transferred 
into ice-cooled tube containing 1 mg/ml EDTA and 
centrifuged at 4℃ to obtain plasma. Plasma renin activ-
ity and concentrations of angiotenisin II and aldoste-
rone were measured by respective radioimmunoassays 
using the commercial kits（SRL, Inc., Tokyo, Japan）.
A portion of the left ventricular free wall tissue was 
homogenized in ten equivalent volumes of saline. A 
0.5 mL aliquot of the homogenate was then mixed with 
36％ hydrochloride and heated to 100℃ for 20 hours. 
Next, the mixture was centrifuged at 1 , 5 0 0 g for 
30 minutes, and a 0.1 mL aliquot of the supernatant was 
mixed with 1.5 mL of 0.3 N hydroxylithium. Hydroxy-
proline content in the reaction product was determined 
by high-performance liquid chromatography, and the 
value was expressed relative to tissue weight8）.
Histological Examination
The cardiac ventricles and descending thoracic aorta 
were excised and weighed. The weight of cardiac ven-
tricles was corrected with the body weight and the 
weight of aorta was expressed as weight per unit area. 
The upper half of cardiac ventricles were fixed in neu-
tral-buffered 8％ formaldehyde solution and embedded 
in paraffin. The 2-mm sections were cut for histologi-
cal examination which was conducted in a blind man-
ner. The sections were stained with Masson trichrome 
and the fibrosis of the left ventricular wall was evalu-
ated. The area stained in blue with aniline was quanti-
fied in ten randomly-selected high-power fields
（x200）using a computer system（Image Quest, Hama-
matsu Photonics；Hamamatsu and MacScope, Mitani 
Co., Fukui, Japan）, and the average percent value was 
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????????　 Time-course changes in body weight （?）, 
systolic blood pressure （?） and pulse rate 
（?） of control untreated SHR and SHR 
treated with azelnidipine （AZL）, olmesartan 
（OLM） or both （Comb）. ＊p＜0.05, †p＜
0.01, ‡p＜0.001 vs. control untreated SHR.
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used for comparison.
Statistical Analysis
Values are expressed as means±SE. Comparison of 
the 4 groups was performed by one-way ANOVA and 
the post-hoc analysis by Dunnett’s multiple-range test. 
Time-course changes in parameters were analyzed by 
two-way ANOVA with post-hoc multiple comparisons 
using the Bonferroni-Dunn test. Non-parametric data 
were analyzed by the Kruskal-Wallis H-test followed 
by Tukey’s method for post-hoc between-group com-
parisons. A p value less than 0 .05 was considered to 
indicate statistical significance.
???????
Physical Measurements and Organ Weights
All the rats have survived and completed the 12-
week study period. Figure 1 shows the time-course 
changes in body weight（panel A）, blood pressure
（panel B）and pulse rate（panel C）during the study 
period. The values of body weight, blood pressure and 
pulse rate at 12 weeks were listed in Table 1 . The 
body weight increases were similar among the control, 
the AZL, the OLM and the combination groups. The 
blood pressures were comparably lowered in the AZL, 
the OLM and the combination groups as compared 
with the control group throughout the study period. 
The pulse rate was significantly reduced in the AZL 
group than in the control group, while it was not sig-
nificantly changed in the OLM or the combination 
group as compared with the control group.
Figure 2 depicts the weights of cardiovascular or-
gans such as the heart and the aorta. The weights of 
cardiac ventricles were significantly reduced in the 
AZL group, the OLM group and the combination group 
as compared with the control group. The reductions in 
cardiac weights were not significantly different be-
tween the 3 antihypertensive treatments. The weight 
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???????　Physical measurements at the end of 12-week study period.
Parameter
Control
（n＝9）
Azelnidipine
（n＝9）
Olmesartan
（n＝9）
Combination
（n＝9）
Body weight, g 337±7 327±7 326±7 322±8
Systolic blood pressure, mmHg 198±5 148±3‡ 143±3‡ 143±3‡
Pulse rate, bpm 370±10 343±7＊ 358±9 376±10
Values are means±SE. ＊ p＜0.05, ‡ p＜0.001 vs. control untreated SHR.
????????　 Cardiovascular organ weights in control untreated SHR and SHR treated 
with azelnidipine （AZL）, olmesartan （OLM） or both （Comb） for 12 
weeks. ＊p＜0.05, ‡p＜0.001 vs. control untreated SHR.
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of descending thoracic aorta per unit area was also sig-
nificantly reduced in the 3 treatment groups to similar 
extents as compared with the control group.
Circulation Levels of renin-Angiotensin-Aldosterone 
System
Figure 3 presents the plasma levels of renin, angio-
tensin II and aldosterone in the 4 experimental groups. 
Plasma renin activity and plasma angiotensin concen-
tration were significantly increased in the SHR groups 
treated with antihypertensive drugs as compared with 
the control untreated SHR. Especially, the increases 
were prominent in the groups given OLM. Regarding 
the aldosterone in plasma, the level was significantly 
increased in the AZL group while it was significantly 
decreased in the OLM and the combination groups as 
compared with the control group.
Evaluation of Cardiac Injury
Echocardiographic data obtained at the end of the 
12-week study period are shown in Figure 4. The mid-
wall fractional shortening, an index of left ventricular 
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????????　 Circulating levels of renin-angiotensin-aldosterone system in control 
untreated SHR and SHR treated with azelnidipine （AZL）, olmesartan （OLM） 
or both （Comb） for 12 weeks. ＊p＜0.05, †p＜0.01, ‡p＜0.001 vs. control 
untreated SHR.
????????　 Parameters of systolic and diastolic function of left ventricle in 
control untreated SHR and SHR treated with azelnidipine （AZL）, 
olmesartan （OLM） or both （Comb） for 12 weeks. ＊p＜0.05, †p＜
0.01 vs. control untreated SHR.
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systolic function, was not significantly different be-
tween the control untreated SHR and the 3 groups of 
SHR given AZL, OLM or the combination therapy. 
With regard to the index of left ventricular diastolic 
function, the E/A ratio of transmitral flow velocity was 
improved in the OLM and the combination groups as 
compared with the control group. However, this pa-
rameter of left ventricular diastolic function did not dif-
fer in the AZL group as compared with the control 
group.
The bar graphs of Figure 5 compare the extents of 
left ventricular wall tissue fibrosis between the 
4 groups of rats. As shown in the left panel, the fibrosis 
area stained in the Masson trichrome sections was sig-
nificantly reduced in the OLM and the combination 
groups as compared with the control group. However, 
the fibrosis area observed in the AZL group was not 
significantly different with the control group. The mea-
surements of hydroxyproline in the left ventricular tis-
sue showed the results similar to the histological find-
ings（right panel, Figure 5）. The content of this amino 
acid composing collagen was lower in the OLM and the 
combination groups than in the control group, however, 
the content was not significantly different between the 
AZL and the control groups.
??????????
Several studies have investigated the protective ef-
fects of antihypertensive drugs against cardiovascular 
organ injuries using various animal models of hyper-
tension, including mineralocorticoid-salt administra-
tion9,10）, renovascular hypertension11〜13）and renal abla-
tion14,15）, in which hypertensive organ injuries progress 
rapidly over a period of several weeks to months. How-
ever, these are more likely the experimental models of 
secondary hypertension and the rapid temporal course 
of organ damage does not accurately reflect the organ 
damage that occurs over a span of decades in humans 
with essential hypertension. In this context, the patho-
physiology of organ damage in SHR may more closely 
parallel to that which occurs in humans with essential 
hypertension16〜18）. Thus, it seems more appropriate to 
evaluate the effects of antihypertensive therapy using 
SHR in order to apply the findings to clinical medicine, 
considering that the majority of hypertensive patients 
are essential hypertension. SHR exhibit cardiac hyper-
trophy and arterial wall thickening with the develop-
ment of hypertension although the organ injury, such 
as renal dysfunction does not occur until a later stage 
of life. Therefore, SHR is thought to be a suitable model 
to evaluate the therapeutic effects against hyperten-
sive injuries in the heart and the arteries.
It has been suggested that the enhancement of re-
nin-angiotensin-aldosterone system （RAAS） is in-
volved in the progression process of cardiovascular tis-
sue and organ injuries19,20）. Particularly, angiotensin II 
promotes hypertrophy of cardiovascular cells, and aldo-
sterone induces fibrosis of the cardiovascular tis-
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????????　 Parameters of left ventricular fibrosis in control untreated SHR and SHR 
treated with azelnidipine （AZL）, olmesartan （OLM） or both （Comb） for 
12 weeks. ＊p＜0.05 vs. control untreated SHR.
Cardiovascular Protection by Antihypertensive Drugs
sues19,20）. Fibrosis and deposition of intercellular matri-
ces, such as collagen, in the cardiac tissue cause 
reduction in left ventricular distensibility21）. Therefore, 
antihypertensive drugs suppressing the RAAS, such as 
ACE inhibitors and ARBs, may be expected to protect 
cardiovascular organs from hypertensive injury inde-
pendent of their effects on blood pressure 1,2）. It has 
been indicated that the growth of cardiovascular cells 
is enhanced in SHR and hypertrophy of cardiovascular 
tissues and organs develops before blood pressure ele-
vation22〜25）. In the present study, the antihypertensive 
therapy including ARB mitigated the increase in left 
ventricular mass and fibrosis of left ventricular tissue. 
This mitigation of cardiac fibrosis, combined with inhi-
bition of cardiac hypertrophy, may account for the ob-
served preservation of myocardial contractility and 
distensibilty by ARB as compared with CCB alone.
Considerable amount of clinical evidence indicates 
that inhibitors of the RAAS improve the prognosis of 
patients with myocardial infarction or heart fail-
ure26〜29）. However, with regard to the primary preven-
tion, it is not necessarily clear if there is an advantage 
to RAAS inhibitors over other classes of antihyperten-
sive drugs in the prevention of coronary artery disease 
and heart failure in hypertensive patients. In CASE-J
（Candesartan Antihypertensive Survival Evaluation in 
Japan）trial 30）, Japanese hypertensive patients with 
high risks of cardiovascular diseases were treated with 
an ARB（candesartan）or a CCB（amlodipine）for an 
average of 3.2 years, which produced no significant dif-
ferences in cardiovascular morbidity or mortality. ALL-
HAT（Antihypertensive and Lipid-Lowering treat-
ment to Prevent Heart Attack Trial）31）is a large-scale 
clinical study in which the effects of a diuretic
（chlorthalidone）, a CCB （amlodipine）, and an ACE in-
hibitor （lisinopril） were compared in hypertensive pa-
tients with high risks of cardiovascular diseases. The 
trial investigators reported that the incidence of heart 
failure showed a nonsignificant trend towards lower 
incidence in the ACE inhibitor group than in the CCB 
group. The VALUE （Valsartan Antihypertensive 
Long-term Use Evaluation） trial 32）, which compared 
the effects of an ARB, valsartan, and a CCB, amlodip-
ine, in high-risk hypertensive patients, also reported a 
nonsignificant trend towards lower incidence of heart 
failure in the ARB group than in the CCB group. Fur-
ther, the meta-analyses of large-scale clinical trials of 
hypertension treatment by the Blood Pressure Lower-
ing Treatment Trialists’ Collaboration33,34）suggested 
that ACE inhibitors were more effective than CCBs in 
preventing heart failure and ARBs have comparable 
effects to ACE inhibitors in this respect. Thus, it is sug-
gested that inhibitors of RAAS are advantageous for 
the primary prevention of cardiac injury in hyperten-
sion.
Epidemiological studies have indicated that an in-
creased heart rate is associated with a higher incidence 
of cardiovascular diseases and a worse prognosis35〜37）. 
Tachycardia due to reflex activation of the sympathet-
ic nervous system is one of the major adverse effects of 
CCB therapy. In this respect, unlike other dihydropyri-
dine CCB, azelnidipine has been shown to inhibit sym-
pathetic nerve activity38）. In the present study, the 
pulse rate of SHR was reduced in the AZL group. This 
property of azelnidipine may be beneficial for the inhi-
bition of cardiovascular events in hypertensive pa-
tients. However, the pulse rate was not significantly 
changed in SHR given lower dose of AZL in combina-
tion with OLM. Therefore, the inhibitory effect of AZL 
on sympathetic nerve activity seems dose-dependent.
Considering the physiological actions of angiotensin 
II, it is quite natural that the plasma renin and angio-
tensin II levels were increased and plasma aldosterone 
is decreased by ARB such as OLM in the present 
study. In addition, OLM has been reported to suppress 
plasma aldosterone more prominently than other 
ARB39）. The reduction in blood pressure and renal per-
fusion pressure by CCB is also expected to enhance 
plasma renin and angiotensin II as observed in this 
study. Regarding the effect on aldosterone secretion, 
the in vitro study has shown that AZL rather inhibits 
aldosterone synthesis in cultured adrenocortical cells40）. 
However, this effect does not seem potent enough to 
counteract the stimulation of RAAS by blood pressure 
reduction in vivo because plasma aldosterone was in-
creased in SHR given AZL in the present study.
The present study demonstrated that the antihyper-
tensive drug therapy including ARB such as OLM is 
superior to the monotherapy using CCB in inhibiting 
the myocardial fibrosis of left ventricle and preserving 
its diastolic function. Thus, long-term antihypertensive 
therapy using the inhibitors of RAAS may be advanta-
??（3） （2015） 133
Takeaki Honda
geous in preventing the occurrence of heart failure in 
hypertensive patients.
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